New bivalent polio vaccine playing key role in global polio eradication

Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial

A child is immunized in Jalalabad, eastern Afghanistan on a memorable day for polio eradication: 16 December 2009, the first day the groundbreaking bivalent oral polio vaccine was ever used. Cornelia Walther/UNICEF

A head to head trial against current poliovirus vaccines has found that the new bivalent oral vaccine against poliovirus, which targets both the remaining types of poliovirus concurrently, induces a stronger immune response than the traditional trivalent vaccine and a similar immune response to the latest monovalent (monovalent type 1 or monovalent type 3)  vaccines. Furthermore, it is easier to administer, allowing children to be immunised against the two remaining types of wild poliovirus in a single oral dose. These are the conclusions of an Article published Online First in The Lancet.

For details, please go to:
http://www.thelancet.com


Related News

   07/02/2024
The frontline worker who lost her feet in a train accident, but never the resolve to eradicate polio from Pakistan
   06/02/2024
To help end all polio transmission and meet the broader health needs of communities now, the GPEI works with a range of partners to integrate polio services with other health programs.
   31/01/2024
Using creative and locally acceptable social behaviour change outreach tactics to engage communities in building trust and reaching children with polio vaccination
   29/01/2024
Philanthropy’s once-in-a-generation opportunity
   26/01/2024
Health leaders call for focused efforts in endemic and most consequential geographies